Press Releases

05.03.2017

Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritis

05.02.2017

Pfizer Reports First-Quarter 2017 Results

04.27.2017

Pfizer Hosts Annual Meeting of Shareholders

04.27.2017

Insphero Announces Agreement With Pfizer To Develop Novel Assays For Predicting Drug-Induced Liver Injury

04.27.2017

Pfizer’s Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer

04.25.2017

Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthrough Approach to Neurodegenerative Disease

04.25.2017

Circle Pharma Announces Expansion Of Series A Financing And Appointment Of James C. Lu To Its Board

04.25.2017

Domain Therapeutics And Pfizer Inc. Enter Into Collaboration Agreement On Biosensall™

04.24.2017

Pivotal Phase III Study Underscores Efficacy Of Zavicefta™ (ceftazidime-avibactam) For Treatment Of Hospital-Acquired Pneumonia, A Leading Cause Of Mortality In Hospitals

04.21.2017

Pfizer Receives Positive CHMP Opinion for BESPONSA® (Inotuzumab Ozogamicin) for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

04.21.2017

Pfizer Unveils ATLAS®, An Interactive, User-Friendly Website That Provides Global Antibiotic Resistance Surveillance Data Across 60 Countries

04.20.2017

Pfizer Invites Public To Listen To Webcast Of April 27 Annual Meeting Of Shareholders